Edwards Lifesciences
1,312 hedge funds and large institutions have $59.8B invested in Edwards Lifesciences in 2022 Q1 according to their latest regulatory filings, with 125 funds opening new positions, 473 increasing their positions, 477 reducing their positions, and 117 closing their positions.
53% more call options, than puts
Call options by funds: $289M | Put options by funds: $189M
7% more first-time investments, than exits
New positions opened: 125 | Existing positions closed: 117
1% less funds holding
Funds holding: 1,319 → 1,312 (-7)
0.77% less ownership
Funds ownership: 82.59% → 81.82% (-0.77%)
1% less repeat investments, than reductions
Existing positions increased: 473 | Existing positions reduced: 477
4% less funds holding in top 10
Funds holding in top 10: 27 → 26 (-1)
10% less capital invested
Capital invested by funds: $66.7B → $59.8B (-$6.97B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
+$196M |
| 2 |
Amundi
Paris,
France
|
+$98.8M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$76.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$72.7M |
| 5 |
CI Investments Inc
Toronto,
Ontario, Canada
|
+$60.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
-$196M |
| 2 |
Brown Advisory
Baltimore,
Maryland
|
-$196M |
| 3 |
Sands Capital Management
Arlington,
Virginia
|
-$113M |
| 4 |
Barclays
London,
United Kingdom
|
-$103M |
| 5 |
Two Sigma Investments
New York
|
-$95.1M |
EW Hedge Fund Activity: Q1 2022 in Review
1,312 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q1 2022, worth a combined $59.8B — down 10% from $66.7B a quarter earlier.
Buyers outnumbered sellers: 125 funds opened new EW positions and 117 closed out — a net gain of 8 holders — while 473 added to existing stakes and 477 trimmed.
The largest buyer was Nuveen, adding an estimated $196M. The largest seller was UBS AM, cutting an estimated $196M.
- 1,312 institutional investors held Edwards Lifesciences (EW) as of Q1 2022, down from 1,319 in Q4 2021.
- Funds reported $59.8B of Edwards Lifesciences stock for Q1 2022, down 10% quarter-over-quarter.
- 125 funds opened new Edwards Lifesciences positions in Q1 2022 and 117 closed out, a net change of +8 holders.
- The largest Edwards Lifesciences buyer in Q1 2022 was Nuveen, an estimated $196M added.
- The largest Edwards Lifesciences seller in Q1 2022 was UBS AM, an estimated $196M sold.
Based on aggregated 13F filings for Q1 2022.